| Description | Ponatinib D8 is a deuterium labeled Ponatinib. Ponatinib is an orally active inhibitor of multi-targeted kinase(Abl, PDGFRα, VEGFR2, FGFR1, and Src with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM, respectively). |
| Target activity | c-Kit:12.5 nM, PDGFRα:1.1 nM, FGFR1:2.2 nM, VEGFR2:1.5 nM |
| Synonyms | AP24534 D8 |
| molecular weight | 540.61 |
| Molecular formula | C29H27F3N6O |
| CAS | 1562993-37-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412. |